ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

cizutamig

Also written as “Cizutamig” and “EMB-06”.

Its studies are mostly in Myasthenia Gravis · Lupus Erythematosus, Systemic · Milk Hypersensitivity · Multiple Myeloma, led by 2 companies.

Drug pageCizutamig: every studyAll 9 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Sep 23, 20255 company-led studies, 2 open or runningNext primary completion: Dec 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
UCB42 open or runningphase 1since Sep 23, 2025Sep 23, 2025Dec 2027phase 1 · NCT07215650
Shanghai EpimAb Biotherapeuticsits history only10 open or runningphase 2since Jan 28, 2021Jan 28, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of UCB only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Aug 11, 2024Named cizutamigINNProposed as its International Nonproprietary Name in WHO's List 131
  2. Sep 23, 2025First studies: 2 phase 1 studiesFirst studyNCT07215663, NCT07215650
  3. Nov 13, 2025Phase 1 study in Healthy Participants StudyNCT07236411 · 24 enrolled · Australia
  4. Dec 23, 2025Phase 1 study in Hypersensitivity, ImmediateNCT07408869 · Australia

Ahead

  1. Dec 2027Primary completion: phase 1 study in Myasthenia GravisNCT07215650
  2. Dec 2027Primary completion: phase 1 study in Lupus Erythematosus, SystemicNCT07215663

TargetBeta

“A tetravalent, bispecific antibody directed against both the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and the T-cell surface antigen CD3, ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
elranatamabrulePfizerphase 415
linvoseltamabruleRegeneron Pharmaceuticalsphase 413
teclistamabruleJohnson & Johnsonphase 411
etentamigAbbViephase 311
ramantamigJohnson & Johnsonphase 38
Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934Sino Biopharmaceuticalphase 34
GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003ruleInnovent Biologicsphase 34
vonsetamigruleRegeneron Pharmaceuticalsphase 23
Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001AbbViephase 22
LVV Expressing VSV Glycoprotein/Anti-CD3 scFv Containing Transgene Encoding for Anti-BCMA CAR KLN-1010rulekelonia-therapeutics-incphase 11

Studies

All 4 UCB leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07408869Hypersensitivity, Immediate · Australia1WithdrawnDec 20260
NCT07236411Healthy Participants Study · Australia1CompletedApr 16, 202624
NCT07215650Myasthenia Gravis · China1RecruitingDec 202744
NCT07215663Lupus Erythematosus, Systemic · China1RecruitingDec 202747

How it is read

Names in the registry

  • “Cizutamig”, 3 entries
  • “cizutamig”, 1 entry
  • “EMB-06”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.